Over the past hour, more than 60 million US dollars have been liquidated across the entire network, mainly long positions

October 5 - The stock price of pharmaceutical company Alector (ALEC.O) surged by 44.20% in pre-market trading, reaching $2.61. The company has entered into a global licensing agreement with Genentech for AL050, an experimental drug developed by ALEC for the treatment of Parkinson's disease. ALEC has granted Genentech the exclusive worldwide rights to develop and commercialize AL050. According to ALEC, the agreement will bring an upfront payment of $100 million and may result in milestone payments of up to $1.17 billion by 2029. The company retains ownership of its ABC technology platform for developing therapies for neurodegenerative diseases, as well as all rights to use the platform in its research and development pipeline. As of the close of the previous trading day, ALEC's stock price had risen by 16.03%. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Due to possible errors in automation or lack of context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters assumes no responsibility for any damage or loss caused by the use of the automated translation.)

October 5 - ** Align Technology (ALGN.O) shares fell 3% in pre-market trading to $139.45 ** Brokerage Evercore ISI downgraded ALGN's rating from "Outperform" to "In Line with the Market" ** The firm cited a "weakening consumer environment," a "sharp slowdown" in September demand indicators, and the potential negative impact of China's volume-based procurement (VBP) in 2027, leading it to adopt a more cautious outlook on Align’s earnings prospects ** VBP (volume-based procurement) is a bulk procurement initiative at the national level in China ** Evercore added that the dental market "has weakened significantly in the third quarter," noting declines in both consumer confidence and expectations ** Deterioration in consumer conditions may have started to affect demand for Invisalign, with Evercore ISI stating that the worsening seen in September "increased the risk that deteriorating consumer conditions may begin to be reflected in Invisalign demand" ** Invisalign is Align’s core business and is projected to contribute approximately $3.2 billions to the company’s total revenue of $4 billions in 2025 ** The broker said early signs of profitability improvement at Align are "beginning to show," but a weak consumer environment and potential VBP headwinds make the process "more challenging" ** As of the previous trading day's close, the stock had declined by about 8% year-to-date.